AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) hit a new 52-week high during trading on Wednesday . The company traded as high as $15.17 and last traded at $15.17, with a volume of 191467 shares trading hands. The stock had previously closed at $14.35.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on AXGN. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday. JMP Securities boosted their price target on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th. Raymond James assumed coverage on shares of AxoGen in a report on Monday, July 1st. They issued an “outperform” rating and a $13.00 price objective for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $15.00 target price on shares of AxoGen in a report on Thursday, June 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.00.
Check Out Our Latest Analysis on AXGN
AxoGen Price Performance
AxoGen (NASDAQ:AXGN – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The firm had revenue of $47.91 million during the quarter, compared to the consensus estimate of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. Analysts anticipate that AxoGen, Inc. will post -0.33 EPS for the current fiscal year.
Institutional Trading of AxoGen
A number of large investors have recently modified their holdings of AXGN. First Light Asset Management LLC increased its position in shares of AxoGen by 336.6% in the second quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider’s stock worth $24,211,000 after purchasing an additional 2,578,147 shares during the last quarter. Assenagon Asset Management S.A. grew its position in AxoGen by 2,014.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider’s stock worth $9,490,000 after acquiring an additional 1,248,823 shares in the last quarter. Divisadero Street Capital Management LP boosted its holdings in shares of AxoGen by 587.2% in the 2nd quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider’s stock worth $4,974,000 after purchasing an additional 587,024 shares in the last quarter. Kent Lake Capital LLC purchased a new position in shares of AxoGen during the 1st quarter valued at about $1,617,000. Finally, Roubaix Capital LLC bought a new stake in AxoGen in the 1st quarter worth approximately $351,000. Institutional investors own 80.29% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Featured Articles
- Five stocks we like better than AxoGen
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- When to Sell a Stock for Profit or Loss
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.